NCT04959981 - A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 2, 2021

Primary Completion Date

April 27, 2023

Study Completion Date

April 27, 2023

Conditions

Advanced Non-squamous Non-small-cell Lung Cancer

Interventions

DRUG

ERAS-007

Administered orally

DRUG

ERAS-601

Administered orally

DRUG

Osimertinib

Administered orally

DRUG

Sotorasib

Administered orally

Trial Locations (11)

10065

Memorial Sloan Kettering Cancer Center, New York

22031

Virginia Cancer Specialists, Fairfax

37203

Sarah Cannon Research Institute (Tennessee Oncology), Nashville

48202

Henry Ford Health System, Detroit

80045

University of Colorado, Aurora

90404

UC Los Angeles, Santa Monica

91010

City of Hope, Duarte

92868

UC Irvine, Chao Family Comprehensive Cancer Center, Orange

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Research Institute, Boston

07601

Hackensack University Medical Center (John Theurer Cancer Center), Hackensack

All Listed Sponsors

lead

Erasca, Inc.

INDUSTRY